Vaccine + chemo induce robust T-cell responses in late-stage cervical cancer

March 1, 2017|ObGyn

AT THE CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM

She said that the most interesting finding from the study may have been that the effect of the vaccine/chemotherapy combination was independent of general immune status.

“So, it doesn’t matter if your immune system is suppressed overall. It’s the quality of players on the field and the focus and specificity of those players that matter, and that’s what they were able to demonstrate, which I think is incredibly powerful,” she said.

She noted, however, that although safety was listed as a study endpoint, Dr. Welters did not provide data on toxicities.

The trial was supported by the Dutch Cancer Society and ISA Pharmaceuticals BV. Dr. Welters reported no conflicts of interest. Dr. McArthur has previously disclosed participation in advisory boards for Celgene, Merck, Spectrum Pharmaceuticals, OBI Pharma, Peregrine Pharmaceuticals, and Syndax Pharmaceuticals, and research support from Bristol-Myers Squibb, MedImmune/AstraZeneca, Eli Lilly, ZIOPHARM Oncology, and Merck.